Life science company MilliporeSigma said on Wednesday that it has extended its ongoing collaboration with Baylor College of Medicine to advance a manufacturing platform to develop a safe and effective COVID-19 vaccine and transition to Phase 1 clinical trials.
Using key learnings from their ongoing collaboration on a schistosomiasis vaccine, MilliporeSigma, along with researchers at Baylor College of Medicine and the Texas Children's Hospital Center for Vaccine Development, is optimising the production process to advance two COVID-19 vaccine candidates, including the CoV RBD219-N1 vaccine candidate expected to enter clinical trials later this year.
As part of the agreement, MilliporeSigma will help to accelerate their suitability for large-scale manufacturing. The collaboration will focus on improvements to production efficiency, yield, robustness, scalability and costs. The goal for the partnership is to develop a suitable manufacturing process and steps that would lead to a scale-up approach suitable for pilot and later industrial production.
Additionally, the partners will develop a new manufacturing platform for a second COVID-19 vaccine candidate to shorten the time to enter into Phase 1 clinical trials.
MilliporeSigma is the life science business of Merck KGaA (ETR:MRK).
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma